Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Epigenetic reprogramming of cancer cells via targeted DNA methylation.

Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, Blancafort P.

Epigenetics. 2012 Apr;7(4):350-60. doi: 10.4161/epi.19507. Epub 2012 Apr 1.

2.

Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer.

Stolzenburg S, Beltran AS, Swift-Scanlan T, Rivenbark AG, Rashwan R, Blancafort P.

Oncogene. 2015 Oct;34(43):5427-35. doi: 10.1038/onc.2014.470. Epub 2015 Feb 16.

3.

Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.

Garcia-Bloj B, Moses C, Sgro A, Plani-Lam J, Arooj M, Duffy C, Thiruvengadam S, Sorolla A, Rashwan R, Mancera RL, Leisewitz A, Swift-Scanlan T, Corvalan AH, Blancafort P.

Oncotarget. 2016 Sep 13;7(37):60535-60554. doi: 10.18632/oncotarget.11142.

4.

Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors.

Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, Blancafort P.

Oncogene. 2007 Apr 26;26(19):2791-8. Epub 2006 Oct 23.

PMID:
17057734
5.

MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells.

Duan H, Zhang HJ, Yang JQ, Oberley LW, Futscher BW, Domann FE.

Antioxid Redox Signal. 2003 Oct;5(5):677-88.

PMID:
14580325
6.
7.

╬┤EF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells.

Fukagawa A, Ishii H, Miyazawa K, Saitoh M.

Cancer Med. 2015 Jan;4(1):125-35. doi: 10.1002/cam4.347. Epub 2014 Oct 15.

8.

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation.

Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV.

BMC Cancer. 2010 Feb 4;10:32. doi: 10.1186/1471-2407-10-32.

9.

Epigenetic reprogramming of human lung cancer cells with the extract of bovine parthenogenetic oocytes.

Wang Z, Dao R, Bao L, Dong Y, Wang H, Han P, Yue Y, Yu H.

J Cell Mol Med. 2014 Sep;18(9):1807-15. doi: 10.1111/jcmm.12306. Epub 2014 May 30.

10.

Re-expression and epigenetic modification of maspin induced apoptosis in MCF-7 cells mediated by myocardin.

Liao XH, Li YQ, Wang N, Zheng L, Xing WJ, Zhao DW, Yan TB, Wang Y, Liu LY, Sun XG, Hu P, Zhou H, Zhang TC.

Cell Signal. 2014 Jun;26(6):1335-46. doi: 10.1016/j.cellsig.2014.03.001. Epub 2014 Mar 6.

PMID:
24607789
11.

Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer.

Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, Strahl BD, Blancafort P.

Nucleic Acids Res. 2012 Aug;40(14):6725-40. Epub 2012 May 4.

12.

DNMT3A and DNMT3B mediate autocrine hGH repression of plakoglobin gene transcription and consequent phenotypic conversion of mammary carcinoma cells.

Shafiei F, Rahnama F, Pawella L, Mitchell MD, Gluckman PD, Lobie PE.

Oncogene. 2008 Apr 17;27(18):2602-12. Epub 2007 Nov 12.

PMID:
17998942
13.

MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma.

Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, Xiao L, Liu X, Wang R, Li X, Wu M, Li G.

Mol Cancer. 2011 Sep 30;10:124. doi: 10.1186/1476-4598-10-124.

14.

DNA methyltransferase-3a interacts with p53 and represses p53-mediated gene expression.

Wang YA, Kamarova Y, Shen KC, Jiang Z, Hahn MJ, Wang Y, Brooks SC.

Cancer Biol Ther. 2005 Oct;4(10):1138-43. Epub 2005 Oct 1.

PMID:
16131836
15.

UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.

Jin W, Chen L, Chen Y, Xu SG, Di GH, Yin WJ, Wu J, Shao ZM.

Breast Cancer Res Treat. 2010 Sep;123(2):359-73. doi: 10.1007/s10549-009-0652-2. Epub 2009 Nov 27.

PMID:
19943104
16.

Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation.

Hervouet E, Vallette FM, Cartron PF.

Epigenetics. 2009 Oct 1;4(7):487-99. Epub 2009 Oct 21.

PMID:
19786833
17.
18.

Epigenetic silencing of maspin gene expression in human breast cancers.

Domann FE, Rice JC, Hendrix MJ, Futscher BW.

Int J Cancer. 2000 Mar 15;85(6):805-10.

19.

Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.

Fleury L, Gerus M, Lavigne AC, Richard-Foy H, Bystricky K.

Oncogene. 2008 Jul 3;27(29):4075-85. doi: 10.1038/onc.2008.41. Epub 2008 Mar 3.

PMID:
18317449
20.

Towards sustained silencing of HER2/neu in cancer by epigenetic editing.

Falahi F, Huisman C, Kazemier HG, van der Vlies P, Kok K, Hospers GA, Rots MG.

Mol Cancer Res. 2013 Sep;11(9):1029-39. doi: 10.1158/1541-7786.MCR-12-0567. Epub 2013 Jun 27.

Supplemental Content

Support Center